表皮生长因子受体表达和扩增在人类胶质瘤中的病理意义。

Pathological significance of epidermal growth factor receptor expression and amplification in human gliomas.

机构信息

Department of Pathology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang ProvinceDepartment of Pathology, Department of Basic Medicine, Xi'an Medical University, Xi'an, Shanxi Province, China.

出版信息

Histopathology. 2012 Oct;61(4):726-36. doi: 10.1111/j.1365-2559.2012.04354.x.

DOI:10.1111/j.1365-2559.2012.04354.x

PMID:22978472

Abstract

AIMS

To investigate epidermal growth factor receptor (EGFR) expression and amplification in gliomas and to assess their association with survival.

METHODS AND RESULTS

Immunohistochemistry and fluorescence in-situ hybridization were performed to analyse EGFR status in 158 cases of primary glioma. Kaplan-Meier survival and Cox regression analyses were performed to analyse the prognosis of patients. Overexpression of EGFR and expression of EGFR variant III (EGFRvIII) were found in 102 cases (64.6%) and 47 cases (29.7%), respectively. Overexpression of EGFR was significantly correlated with World Health Organization (WHO) grade and Karnofsky performance score (KPS) (both P < 0.05). Expression of EGFRvIII was significantly correlated with WHO grade, gender, age, and KPS (all P < 0.05). EGFR amplification was found in 46 cases (29.1%), and was significantly correlated with WHO grade, age, KPS and EGFR overexpression (all P < 0.05). Cox multifactor analysis showed that EGFR amplification was an independent unfavourable prognostic factor for human gliomas at all ages, and EGFRvIII was an independent prognostic factor in patients older than 60 years.

CONCLUSION

EGFR amplification and EGFRvIII expression were associated with an unfavourable prognosis for patients of all ages, and for those older than 60 years, respectively. The differing significance of EGFR status in young and old glioma patients and its impact on prognosis needs further study.

摘要

目的

研究表皮生长因子受体（EGFR）在脑胶质瘤中的表达和扩增情况，并评估其与生存的关系。

方法和结果

对 158 例原发性脑胶质瘤进行免疫组织化学和荧光原位杂交分析 EGFR 状态。采用 Kaplan-Meier 生存分析和 Cox 回归分析评估患者的预后。发现 102 例（64.6%）存在 EGFR 过表达，47 例（29.7%）存在 EGFR 变异型 III（EGFRvIII）表达。EGFR 过表达与世界卫生组织（WHO）分级和 Karnofsky 表现评分（KPS）显著相关（均 P<0.05）。EGFRvIII 表达与 WHO 分级、性别、年龄和 KPS 显著相关（均 P<0.05）。发现 46 例（29.1%）存在 EGFR 扩增，与 WHO 分级、年龄、KPS 和 EGFR 过表达显著相关（均 P<0.05）。Cox 多因素分析显示，EGFR 扩增是所有年龄段脑胶质瘤患者的独立不良预后因素，而 EGFRvIII 是 60 岁以上患者的独立预后因素。